Drug Delivery Systems

Goals of a novel drug delivery system:

  • Increased bio-availability of beneficial active pharmaceutical ingredients (API)

  • Reduction of adverse effects of non-beneficial APIs

  • Re-compounding of an existing drug for improved efficacy

  • Development of new drugs using better technologies

Join us in a journey towards the future.

The C in ABC = Cell

The traditional method of developing new pharmaceutical molecules can be time-consuming and expensive, often falling short of the goal to improve outcomes. The Quantum Dot Diagnostics Platform of GeneHarmonics Inc., will create novel ways of monitoring biomarkers in drug development.

  • GeneHarmonics’ Quantum Dot technology can measure the trends of affected biomarkers during clinical trials.

  • BitHarmonics can aggregate data from population models to determine the effectiveness of existing drugs in population settings

“We have developed a technology that some of my partners said may have world changing implications. But I believe change cannot rely on technology alone. There must be a convergence of science, multi-sectoral and multi-disciplinarian cooperation that is borderless, beyond culture, language and all the usual barriers that divide us. What if we use our differences instead to work together and rally around a moral purpose of saving lives – because that is a sentiment that should be common to all of us.”


We have the foundational technology to develop rapid and quantitative diagnostic tests for different biomarkers using Quantum Dots.  Our patented Quantum Dot technology makes our diagnostic tests ideal for immunity level detection, infectious disease management, and biomarker monitoring in both personal health and drug delivery technology.


A companion to our Quantum Dot technology is a secured, encrypted data platform.  Our platform captures and organizes the data necessary to monitor biomarker trends in personal health, expedite drug development through biomarker tracking, and anonymize positive or negative results in infectious disease management.


We are partnering with several pharmaceutical companies to develop novel drug delivery systems.   Through our Quantum Dot diagnostic technology and our data collection platform we can expedite new drugs with higher bioavailability of active pharmaceutical ingredients (API) and  substantially reduced toxicity and side effects.


Our Bio-diagnostics Team

Meet our team leading the research and development of our Quantum Dot diagnostic devices. We are working on miniaturization, quantification of biomarkers for drug delivery, data integration and anonymization for infectious disease management, multi-diagnostics, and other innovations for the next generation of our Quantum Dot devices.

Doug Thomas

Doug is one of the leading drug formulators in Silicon Valley. Doug is of the scientists in GeneHarmonics, Inc. He will handle the integration of  drug delivery technologies, clinical trials, research and coordination with other scientists from partner pharmaceutical companies.

Gil Masiglat

Gil handles strategic partnerships from Asia. Gil is already finalizing agreements with some of the biggest pharmaceutical companies in Asia that are respected in the field of drug development, manufacturing, and distribution. Hospitals who will participate in clinical trials are also in-place.

Next Generation Drug Delivery Systems

The next set of drugs will allow for improved bio-availability of beneficial active pharmaceutical ingredients and reduced or eliminated adverse events. Side effects will no longer be a factor in intervention.

Contact Us

Transforming Healthcare Therapeutics

Some of the existing drugs on the market can be reformulated to be more effective and less toxic.

Contact Us